Novel Approaches to Acute Myeloid Leukemia Immunotherapy
Ofrat Beyar‐Katz(Rambam Health Care Campus), Saar Gill(Parker Institute for Cancer Immunotherapy)
Cited by 63
Related Papers
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
|Cancer Discovery|2020|297
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
|Nature Medicine|2025|189
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170